Valuation: Nurix Therapeutics, Inc.

Market Cap 2.84B 2.54B 2.34B 2.13B 3.99B 269B 4.05B 28.2B 11.11B 141B 10.67B 10.44B 447B P/E 2026 *
9.36x
P/E 2027 * -15.8x
Enterprise Value 2.04B 1.82B 1.68B 1.52B 2.86B 193B 2.9B 20.21B 7.96B 101B 7.65B 7.48B 320B EV / Sales 2026 *
2.74x
EV / Sales 2027 * 15.7x
Free-Float
98.73%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week+2.85%
Current month+8.22%
1 month-0.04%
3 months+8.73%
6 months+54.30%
Current year+35.27%
1 week 24.26
Extreme 24.265
26.34
1 month 21.23
Extreme 21.23
26.34
Current year 14.01
Extreme 14.01
28.23
1 year 10.28
Extreme 10.28
28.23
3 years 4.22
Extreme 4.22
29.56
5 years 4.22
Extreme 4.22
36.24
10 years 4.22
Extreme 4.22
52.38
Manager TitleAgeSince
Chief Executive Officer 64 2014-09-17
Director of Finance/CFO 60 2016-02-29
Chief Tech/Sci/R&D Officer - 2019-07-31
Director TitleAgeSince
Director/Board Member 64 2014-09-17
Chairman 73 2019-07-31
Chairman 73 2024-05-19
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 Exercice

Chief Technology Officer

4,356 0.0042%
10/14/26 Exercice

Chairman

67,749 0.0653%
10/2/26 Exercice

Compliance Officer

17,358 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%+2.85%+141.39%+447.12% 2.84B
-4.10%-8.35%+38.48%+66.99% 66.22B
-0.41%+3.27%+10.46%+73.74% 55.2B
+0.74%+4.04%+12.18%+91.76% 52.79B
-0.34%+1.65%+26.47%+49.98% 45.53B
-1.28%+2.33%+22.09%+126.87% 43.94B
-4.02%-0.50%+255.45%+925.99% 41.64B
-1.67%+8.06%+14.17%+56.67% 34B
-8.38%-9.01%+25.65%-1.82% 25.84B
+1.30%+4.94%+38.23%+28.03% 23.51B
Average -1.93%+4.08%+58.46%+186.53% 39.15B
Weighted average by Cap. -1.83%+3.48%+48.60%+162.37%

Financials

2026 *2027 *
Net sales 745M 665M 613M 557M 1.05B 70.55B 1.06B 7.39B 2.91B 36.96B 2.8B 2.74B 117B 123M 110M 101M 92.19M 173M 11.67B 176M 1.22B 482M 6.11B 463M 453M 19.37B
Net income 342M 306M 282M 256M 481M 32.44B 488M 3.4B 1.34B 17B 1.29B 1.26B 53.84B -198M -177M -163M -148M -278M -18.77B -282M -1.97B -774M -9.83B -744M -728M -31.15B
Net Debt -805M -719M -663M -603M -1.13B -76.29B -1.15B -7.99B -3.15B -39.97B -3.02B -2.96B -127B -907M -809M -747M -678M -1.27B -85.89B -1.29B -9B -3.54B -45B -3.4B -3.33B -143B
Projected Income Statement - Annual - Nurix Therapeutics, Inc.
Logo Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
Employees
317
Date Price Change Volume
26-10-22 US$25.66 -1.38% 744,343
26-10-21 US$26.02 -0.31% 2,928,500
26-10-20 US$26.10 +4.69% 3,979,773
26-10-19 US$24.93 +2.09% 3,064,083
26-10-16 US$24.42 -2.12% 4,318,359
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Nurix Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.02USD
Average target price
34.50USD
Spread / Average Target
+32.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Nurix Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. NRIX Stock